Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ:COYA)

4.900 +0.040 (+0.83%)
Streaming Delayed Price Updated: 10:04 AM EDT, Jul 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 65,071
Open 4.900
Bid (Size) 4.900 (900)
Ask (Size) 4.950 (100)
Prev. Close 4.860
Today's Range 4.800 - 5.360
52wk Range 3.710 - 7.750
Shares Outstanding 9,947,915
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
From Coya Therapeutics, Inc.
Via Business Wire

Performance

YTD
-13.3%
-13.3%
1 Month
+0.2%
+0.2%
3 Month
+10.1%
+10.1%
6 Month
+3.2%
+3.2%
1 Year
-20.5%
-20.5%

More News

Read More
News headline image
Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces $11.1 Million Private Placement
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Get insights into the top gainers and losers of Friday's pre-market session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is Coya Therapeutics, Inc. - Common Stock publicly traded?
Yes, Coya Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Coya Therapeutics, Inc. - Common Stock trade on?
Coya Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Coya Therapeutics, Inc. - Common Stock?
The ticker symbol for Coya Therapeutics, Inc. - Common Stock is COYA on the Nasdaq Stock Market
What is the current price of Coya Therapeutics, Inc. - Common Stock?
The current price of Coya Therapeutics, Inc. - Common Stock is 4.900
When was Coya Therapeutics, Inc. - Common Stock last traded?
The last trade of Coya Therapeutics, Inc. - Common Stock was at 07/14/26 10:04 AM ET
What is the market capitalization of Coya Therapeutics, Inc. - Common Stock?
The market capitalization of Coya Therapeutics, Inc. - Common Stock is 48.75M
How many shares of Coya Therapeutics, Inc. - Common Stock are outstanding?
Coya Therapeutics, Inc. - Common Stock has 49M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.